Sunshine Biopharma, Inc. (SBFM) - Cash Funds Calculated per Share

The foundation of growth for Sunshine Biopharma (SBFM) is patent scalability without capital expenditures, as evidenced by the company's cash per share. Future intellectual property will ensure monopoly pricing power, although the business is currently depleting reserves due to operating losses. The current metric holds around 17.65, clearly demonstrating the dynamics of the issuer's cash cushion.
Comprehensive metric breakdowns and analytics for Sunshine Biopharma, Inc. (SBFM)

Institutional capital evaluates Sunshine Biopharma (SBFM) through the lens of liquidity to determine the business's survival horizon. This metric is calculated as the ratio of total cash to the number of shares, measuring the real equity value of cash. By analyzing the free cash flow per share chart from GURU.Markets, an investor can see the capital burn rate. For a company in the early stages of R&D, this is a critical marker of the ability to fund development without new issuances. A low level of this metric confirms the asset's high financial instability.